A Phase II Trial of the Cyclin-dependent Kinase Inhibitor Flavopiridol in Patients with Previously Untreated Stage IV Non-Small Cell Lung Cancer

Purpose: Flavopiridol is a potent cyclin-dependent kinase inhibitor with preclinical activity against non-small cell lung cancer (NSCLC), inhibiting tumor growth in vitro and in vivo by cytostatic and cytotoxic mechanisms. A Phase II trial was conducted to determine the activity and toxicity of flav...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2001-06, Vol.7 (6), p.1590-1599
Hauptverfasser:	SHAPIRO, Geoffrey I, SUPKO, Jeffrey G, PATTERSON, Angus, LYNCH, Cathy, LUCCA, Joan, ZACAROLA, Patrick F, MUZIKANSKY, Alona, WRIGHT, John J, LYNCH, Thomas J, ROLLINS, Barrett J
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antineoplastic agents Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antineoplastic Agents - toxicity Biological and medical sciences Carcinoma, Non-Small-Cell Lung - drug therapy Chemotherapy Cyclin-Dependent Kinases - antagonists & inhibitors Disease Progression Dose-Response Relationship, Drug Enzyme Inhibitors - therapeutic use Female Flavonoids - pharmacokinetics Flavonoids - therapeutic use Flavonoids - toxicity Gas Chromatography-Mass Spectrometry Humans Lung Neoplasms - drug therapy Male Medical sciences Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Piperidines - pharmacokinetics Piperidines - therapeutic use Piperidines - toxicity Time Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!